Publications by authors named "Anneli Wahlberg"
Aims: To determine CYP2C19 and CYP2D6 activity in patients with multiple sclerosis (MS) before and during interferon (IFN)-beta treatment.
Methods: CYP2C19 and CYP2D6 activities were assessed using the probe drugs mephenytoin and debrisoquine, respectively. Urinary mephenytoin (S/R) and debrisoquine (debrisoquine/hydroxy-debrisoquine) metabolic ratios (MR) were determined in 10 otherwise healthy Caucasian multiple sclerosis (MS) patients in the initial stage of the disease, prior to and 1 month after commencing treatment with IFN-beta (Avonex, Rebif or Betaferon).
Article Synopsis
- The study aimed to evaluate whether low doses of five different drugs can be safely administered together to test the function of various cytochrome P450 enzymes.
- Following a washout period, participants were given the drugs separately and then simultaneously, with blood and urine samples collected for analysis.
- Results showed that most enzyme activities were unchanged, except for CYP2D6, where co-administration led to significant inhibition of debrisoquin metabolism, highlighting potential interactions among the drugs.